Indivior Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Indivior Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Indivior Pharmaceuticals Inc achieved a return on average assets (ROA) of 28.37 % in its second quarter of 2026, this is above INDV's average return on assets of 9.92%.
Indivior Pharmaceuticals Inc assets over the 12 months ending in its second quarter of 2026 are valued at $1,255 million

ROA has improved compared to 19.14% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 34 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 247, from total ROA ranking in the first quarter of 2026 at 386.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-16.94 %	-12.95 %	-33.87 %	-56.13 %	-21.6 %
Y / Y Net Income Change	577.78 %	89.36 %	390.48 %	90.91 %	-
Net Income (TTM) in million	356	252	210	128	108
Return On Assets (TTM)	28.37 %	19.14 %	15.43 %	8.45 %	5.49 %
INDV's Total Ranking	# 247	# 386	# 662	# 861	# 2646
Total Assets (TTM) in million	1,206	1,197	1,201	1,416	1,452
Seq. Total Assets Change	0.75 %	-0.33 %	-15.18 %	-2.48 %	5.6 %
Seq. Net Income Change	37.08 %	-13.59 %	145.24 %	133.33 %	-61.7 %

INDV's 5 Years Annual ROA >> Back to INDV Management Effectiveness >> Compare INDV ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 19
Sector	# 35
Overall	# 137

Return On Assets Statistics
High	Average	Low
28.21 %	9.92 %	-0.44 %
(Jun 30 2026)		(Mar 31 2025)

Financial Statements
Indivior Pharmaceuticals Inc 's Assets	$ 1,206 million	INDV's Balance sheet
Indivior Pharmaceuticals Inc 's Income	$ 122 million	Quarterly INDV's Income Statement
INDV's Income by Division		See INDV's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	FY	FY
Y / Y Total Assets Change	-22.17 %	-48.77 %	-	-	-
Total Assets in million	1,148	1,475	2,879	0	0
Y / Y Net Income Change	10400 %	0 %	-	-	-
Net Income in million	210	2	2	0	0
Annual Return On Assets	18.29 %	0.14 %	0.07 %	-	-

INDV's 5 Years Annual ROA >> Back to INDV Management Effectiveness >> Compare INDV ROA to its Competitors

Comment on INDV's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 18.29 % compared to prior year, due to annual net income growth of 10400 % to $210.00 million, and due to decline of value in Indivior Pharmaceuticals Inc 's assets by -22.17 % to $1,148.00 million, compared to $1,148.00 a year before.

More Return On Assets Ratios
INDV's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
INDV's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for INDV's Competitors
Subscribers only: Roa for Indivior Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for INDV's Customers

You may also want to know
INDV's Roi	INDV's Inventory Turnover Ratio	INDV's Growth Rates	INDV's Dividend Comparisons
	INDV's Profitability Ratios	INDV's Asset Turnover Ratio	INDV's Dividend Growth
INDV's Roe	INDV's Valuation Ratios	INDV's Financial Strength Ratios	INDV's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Rigel Pharmaceuticals Inc	72.27 %
Actinium Pharmaceuticals Inc	71.73 %
Sanuwave Health Inc	71.60 %
Exelixis Inc	70.51 %
Rallybio Corporation	64.51 %
Oramed Pharmaceuticals Inc	64.18 %
Fortress Biotech Inc	60.88 %
Atlantic Coastal Acquisition Corp Ii	54.09 %
Lensar Inc	47.48 %
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %
Idexx Laboratories Inc	33.61 %
Tg Therapeutics Inc	33.59 %
Meiragtx Holdings Plc	29.37 %
Indivior Pharmaceuticals Inc	28.21 %
Qhslab Inc	27.12 %
Adma Biologics Inc	26.58 %
Mettler toledo International Inc	24.86 %
Medpace Holdings Inc	24.84 %
Caredx Inc	24.81 %
Acadia Pharmaceuticals Inc	24.38 %
Eli Lilly And Company	21.97 %
Innoviva Inc	21.64 %
Vaxart Inc	20.85 %

Date modified: 2026-09-12T18:35:12+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.